News

Treatment with Andembry (garadacimab) may help prevent recurrent hereditary angioedema (HAE) attacks for years, with longer attack-free periods linked to better quality of life, according to a study based on statistical predictions. The study, “Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack-Free Probability and Quality…

People with hereditary angioedema (HAE) showed better disease control and quality of life during treatment with Andembry (garadacimab-gxii), a small real-world study in Germany found. Many were also able to go longer between injections under medical supervision. After about six months, nearly all patients who were assessed had…

A single oral dose of the experimental treatment deucrictibant rapidly brought hereditary angioedema (HAE) attacks under control, significantly shortening the time to symptom relief, stopping attacks from worsening sooner, and speeding complete symptom resolution compared with a placebo. That’s according to results from the now-completed Phase 3 RAPIDe-3 trial…

The U.S. Food and Drug Administration (FDA) has approved an oral pellet version of Orladeyo (berotralstat) for teens and adults with hereditary angioedema (HAE), expanding access to a formulation previously available only for young children. Developed by Biocryst Pharmaceuticals, the once-daily preventive treatment was previously approved as…

Specialists treating hereditary angioedema (HAE) across Latin America largely agree with international treatment guidelines, but high costs, limited access to medications, and frequent supply interruptions may keep patients from getting the care they need, a survey has found. Nearly two-thirds of the 30 specialists surveyed across 10 countries reported…

A 73-year-old man with influenza A, the major cause of seasonal flu, developed sudden upper-lip swelling about one hour after taking the antiviral Tamiflu (oseltamivir), raising suspicion that the medicine may have triggered angioedema, according to a case report. After Tamiflu was stopped, the swelling gradually improved and resolved…

Nearly one in five people with hereditary angioedema (HAE) left their latest swelling attack untreated, most often because it seemed mild or did not limit their activities, an international survey has found. Preventive treatment brought its own challenges, as forgetting doses and difficulty fitting medication into daily routines were…

Long-term preventive therapy can keep people with hereditary angioedema (HAE) free from swelling attacks requiring treatment for extended periods, according to a real-world study in Germany that found that more than one-third of HAE patients on prophylactic meds had no attacks needing on-demand treatment for at least one year.

The experimental therapy barzolvolimab can reduce disease activity in people with chronic spontaneous urticaria (CSU) — an inflammatory disorder characterized by recurrent itching and hives — who experience angioedema, according to results from two Phase 3 clinical trials. Celldex Therapeutics, the company developing barzolvolimab, plans to use the…

Dawnzera (donidalorsen), a preventive therapy used to reduce the risk of swelling attacks in people with hereditary angioedema (HAE), has been approved in Canada for adults and adolescents ages 12 and older. The decision by Health Canada follows Dawnzera’s approval for the same indication in the U.S. last…